The integration of the NCCN Chemotherapy Order Templates (NCCN Templates®) into the Flatiron Health OncoEMR® electronic health record will allow for access to evidence-based treatment protocols based on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
FORT WASHINGTON, PA
The National Comprehensive Cancer Network® ( NCCN®) is collaborating with Flatiron Health to integrate the NCCN Chemotherapy Order Templates (NCCN Templates®) into the Flatiron Health OncoEMR® electronic health record, starting initially with breast, colon, and non-small cell lung cancers, with plans to expand to additional tumor types.
“Breast, colon, and lung cancers are three of the most common cancers in the United States, and the decision to incorporate NCCN Templates, beginning with these three diseases, into OncoEMR indeed will enhance the safety and effectiveness of care for many patients in community and academic settings alike,” said Robert W. Carlson, MD, CEO, NCCN. “NCCN is eager to collaborate with Flatiron Health on this significant endeavor.”
OncoEMR is a cloud-based electronic health record designed specifically for cancer centers. As part of this integration, cancer care providers will be able to easily select the NCCN Templates® directly within OncoEMR at the point of care.
“We are pleased to collaborate with NCCN on this new offering, which will enhance the delivery of care for patients across the Flatiron provider network,” said Bobby Green, MD, vice president, clinical strategy and senior medical director, Flatiron Health. “Seamless, integrated access to the NCCN Templates within OncoEMR will assist physicians in referencing the latest evidence-based treatment regimens at the point of care.”
In addition, OncoEMR will link to NCCN.org so that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are available to end users as a reference. The information contained in the NCCN Templates is based on the NCCN Guidelines®. NCCN Templates include chemotherapy and immunotherapy regimens with literature support, supportive care agents, monitoring parameters, and safety instructions.
NCCN continues to add to the library of chemotherapy order templates to improve the safe and effective use of drugs and biologics in cancer care.
The NCCN Templates enhance patient safety by assisting health care providers with standardization of patient care, reduction in medication errors, and anticipation and management of adverse effects.
In January 2015, NCCN and Flatiron announced a collaboration to launch a novel oncology outcomes database to provide the opportunity to analyze key quality and outcomes metrics and identify trends and patterns in the care of patients with cancer.
For more information about the NCCN Templates, visit NCCN.org/templates.
About The National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 26 of the world’s leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.
The NCCN Member Institutions are: Fred & Pamela Buffett Cancer, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at BarnesJewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.
Clinicians, visit NCCN.org. Patients and caregivers, visit NCCN.org/patients.
About Flatiron Health
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.
